Shilanski & Associates’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$214K Buy
759
+7
+0.9% +$2.03K 0.06% 105
2025
Q2
$210K Sell
752
-1
-0.1% -$283 0.06% 101
2025
Q1
$235K Buy
+753
New +$222K 0.07% 91
2024
Q4
Sell
-830
Closed -$268K 102
2024
Q3
$268K Sell
830
-70
-8% -$22.9K 0.09% 83
2024
Q2
$281K Sell
900
-4
-0.4% -$1.18K 0.09% 79
2024
Q1
$257K Sell
904
-176
-16% -$51.5K 0.09% 83
2023
Q4
$311K Sell
1,080
-60
-5% -$16.3K 0.12% 75
2023
Q3
$306K Buy
1,140
+1
+0.1% +$250 0.12% 81
2023
Q2
$253K Sell
1,139
-43
-4% -$9.98K 0.1% 87
2023
Q1
$299K Buy
1,182
+7
+0.6% +$1.72K 0.13% 77
2022
Q4
$308K Sell
1,175
-802
-41% -$215K 0.13% 83
2022
Q3
$446K Buy
1,977
+500
+34% +$121K 0.16% 77
2022
Q2
$359K Sell
1,477
-65
-4% -$15.9K 0.17% 73
2022
Q1
$373K Sell
1,542
-107
-6% -$24.6K 0.16% 80
2021
Q4
$371K Sell
1,649
-77
-4% -$16.3K 0.16% 77
2021
Q3
$367K Buy
1,726
+170
+11% +$39.1K 0.17% 80
2021
Q2
$379K Sell
1,556
-7
-0.4% -$1.72K 0.18% 78
2021
Q1
$389K Buy
+1,563
New +$373K 0.21% 76

Other funds holding AMGN

Shilanski & Associates's AMGN Position: Q3 2025 in Review

Shilanski & Associates increased its Amgen (AMGN) stake by 0.93% in Q3 2025, buying an estimated $2.03K and bringing the position to 759 shares worth $214K. The position accounts for 0.06% of the portfolio, ranked #105.

Shilanski & Associates first reported a position in AMGN in Q1 2021 and has held it in 18 quarters since. The position peaked at $446K in Q3 2022. 2,826 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.

  • Shilanski & Associates held 759 shares of Amgen worth $214K as of Q3 2025.
  • Shilanski & Associates bought 7 Amgen shares in Q3 2025, an estimated $2.03K.
  • Amgen made up 0.06% of Shilanski & Associates's portfolio in Q3 2025, its #105 holding.
  • Shilanski & Associates first reported a position in Amgen in Q1 2021 and has held it in 18 quarters since.
  • Shilanski & Associates's Amgen position peaked at $446K in Q3 2022.
  • 2,826 funds tracked by Wall St. Rank held Amgen as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.